Catalent CEO to remain in charge of contract drugmaker after Novo completes buyout
21/10/2024 12:12
Oct 21 (Reuters) - Catalent CTLT.N president and CEO
Alessandro Maselli said on Monday he will continue to lead the
contract drugmaker after it is acquired by Novo Holdings, the
controlling shareholder of weight-loss drug manufacturer Novo
Nordisk NOVOb.CO .
Maselli's open letter comes on the back of increased
criticism regarding Novo Holding's acquisition of Catalent that
could threaten competition in weight-loss drugs and cutting-edge
gene therapies.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini
Ganguli)
((Leroy.Dsouza@thomsonreuters.com;))
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled